RVMD CFO exercises 10,000 options at $17, sells 10,000 at $64

Revolution Medicines (RVMD) reported an insider transaction on a Form 4.

Accepted by SEC EDGAR 11/13/2025 - 04:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.

After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.

Insider Trade Summary

Exercise and Sale: 10,000 shares ($470K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Anders Jack

Role Chief Financial Officer

Sold 10,000 shs ($640K)

Approx. gross sale proceeds $640K

Approx. exercise cost $170K

Approx. pre-tax spread $470K

Share of Position Sold 8.3%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$17.00	$170K
Sale	Common Stock	10,000	$64.00	$640K

Holdings After Transaction: Stock Option (Right to Buy) — 5,418 contracts (Direct); Common Stock — 110,994 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 15,418 to 5,418 contracts (Direct); Common Stock, 110,994 to 110,994 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
2. F2. Includes 48,275 restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD’s CFO report?

CFO Jack Anders exercised 10,000 options at $17 and sold 10,000 shares at $64 on 11/11/2025.

Was the RVMD transaction under a 10b5-1 plan?

Yes. It was made pursuant to a Rule 10b5-1 plan adopted on 12/16/2024.

How many RVMD shares does the CFO own after the trades?

He beneficially owned 110,994 shares following the reported transactions.

How many RSUs are included in the CFO’s ownership at RVMD?

His beneficial ownership includes 48,275 restricted stock units.

What was the exercise price and sale price in the RVMD Form 4?

Options were exercised at $17 per share, and shares were sold at $64 per share.

What option award details were disclosed for RVMD’s CFO?

The option had a $17 exercise price, exercisable from 02/12/2024 to 02/11/2030, with 5,418 derivative securities remaining owned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		M(1)		10,000	A	$17	120,994(2)	D
Common Stock	11/11/2025		S(1)		10,000	D	$64	110,994(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	11/11/2025		M			10,000	02/12/2024	02/11/2030	Common Stock	10,000	$0	5,418	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.

2. Includes 48,275 restricted stock units.

	/s/ Jack Anders	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.